Danish Genmab reports updated phase 2 data for petosemtamab in combination with chemotherapy in metastatic colorectal cancer.
The objective response rate was 75 percent in the first-line setting and 67 percent in the second-line setting. Among patients with left-sided tumors in the first-line setting, it was 81 percent.
A total of 79 patients were treated.
Median follow-up was 5.9 and 7.1 months, respectively. The results support the company’s ongoing global phase 3 studies.
